摘要
目的观察白介素-11(IL-11)对异基因造血干细胞移植治疗复发难治性淋巴瘤血小板恢复的影响及其不良反应。方法选取2011年1月—2014年1月应用异基因造血干细胞移植治疗16例复发难治性淋巴瘤,随机分为IL-11治疗组和对症治疗组,对症治疗组仅接受输血小板等对症支持治疗,IL-11治疗组在对症治疗组基础上于移植后7 d起应用IL-11 2400万U/d,连用14 d,预处理方案为改良BU/CY方案,移植后观察两组患者血小板计数(PLT)恢复至≥20×109/L和≥50×109/L的时间、血小板输注次数及无病生存等情况。结果两组患者均获造血重建,IL-11治疗组移植后PLT恢复至≥20×109/L和≥50×109/L的时间及辐照血小板输注次数均较对症治疗组少(P<0.05)。IL-11治疗组有2例发生恶心、呕吐、头痛等一过性不良反应,随访至2015年1月,两组患者无病生存率分别为50%和62.5%,差异无统计学意义(P>0.05)。结论异基因造血干细胞移植治疗复发难治性淋巴瘤过程中应用IL-11有加速血小板恢复的作用,IL-11不良反应轻微、耐受性好。
Objective To observe the effect and adverse reactions of interleukin-11（ IL-11） for platelet recovery of patients with relapsed and refractory lymphoma by haploidentical hematopoietic stem cell transplantation. Methods A total of 16 patients with relapsed and refractory lymphoma undergoing haploidentical allogeneic hematopoietic stem cell transplantation during January 2011 and January 2014,were recruited in this study. The patients were randomly divided into IL-11 treatment group（ n = 8） and symptomatic treatment group（ n = 8）. The symptomatic treatment group received symptomatic supporting treatments such as platelet transfusion,while the IL-11 treatment group was given additional IL-112400 million U / d for 14 d on the 7thd after the transplantation based on the symptomatic supporting treatments. The modified Busulfan / Cyclophosphamide（ BU / CY） was used as preparative regimen. The times of platelet（ PLT） count equal to or over 20 × 10^9/ L and 50 × 10^9/ L,the condition of disease free survival after the transplantation and platelet infusion times were observed. Results All the patients acquired hematopoietic reconstruction. The times of PLT count equal to or over 20 × 10^9/ L and 50 × 10^9/ L and irradiated platelet infusion times in the IL-11 group were less than those in the control group（ P〈0. 05）. In IL-11 group,2 patients had transient adverse reactions such as nausea,vomiting and headache. With follow-up to January 2015,the disease free survival rates were 50% in IL-11 group and 62. 5% in control group respectively,but the difference was not statistically significant（ P〉0. 05）. Conclusion IL-11 in application of patients with relapsed and refractory lymphoma by haploidentical hematopoietic stem cell transplantation can accelerate platelet recovery with mild adverse reactions and good tolerance.
出处
《解放军医药杂志》
CAS
2016年第3期72-75,共4页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
北京市首都临床特色课题(Z151100004015218)
关键词
白介素-11
造血干细胞移植
淋巴瘤
Interleukin-11
Hematopoietic stem cell transplantation
Lymphoma
